Investing.com - Lyra (NASDAQ: LYRA) reported first quarter EPS of $-0.460, $0.05 worse than the analyst estimate of $-0.414. Revenue for the quarter came in at $0.00 versus the consensus...
Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis...
-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra's Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN, Mass., Feb. 06, 2023 (GLOBE...
With the Newport upgrade, Lyra is also now integrated with GMX perpetuals, allowing users to benefit from improved capital efficiency and user experience.
Investing.com - Lyra reported on Tuesday third quarter {{erl-1160914||earnings that beat analysts' forecasts and revenue that topped expectations. Lyra announced earnings per share of...
Investing.com – U.S. equities were higher at the close on Tuesday, as gains in the Consumer Services, Consumer Goods and Technology sectors propelled shares higher. At the close in NYSE,...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
